NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDLenalidomide  Malignant disease and immunosuppression, Other immunomodulating drugs, 08.02.04
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Lenalidomide Lenalidomide [Specialist Drug] Malignant Disease, Immunotherapy Responsive Malignancy, Immunosuppressants Thalidomide And Related Analogues
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
MHRA Drug Safety Update (February 2011) - Lenalidomide: risk of thrombosis and thromboembolism
NICE TA 695 Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
NICE TA171: Multiple myeloma - lenalidomide
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (superseded by NICE TA870)
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (superseded by TA870)
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
NICE TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
NICE TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma (not recommended)
NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable